Search
Sysmex Suisse
Schweiz | DE
Unternehmen
Unternehmen
Back
Unternehmen
Über uns
Über uns
Back
Qualität & Nachhaltigkeit
Qualität & Nachhaltigkeit
Back
News & Events
News & Events
Back
Karriere
Karriere
Back
Kontakte
Kontakte
Back
Produkte
Produkte
Back
Produkte
Diagnostik
Diagnostik
Back
Point of Care Lösungen
Point of Care Lösungen
Back
Pathologie
Pathologie
Back
Oncology Testing
Oncology Testing
Back
Laboratory Equipment
Laboratory Equipment
Back
Service
Service
Back
Service
Technischer Service
Technischer Service
Back
Qualitätskontrolle & Online Service
Qualitätskontrolle & Online Service
Back
Dokumenten-Center & Downloads
Dokumenten-Center & Downloads
Back
Akademie
Akademie
Back
Akademie
Wissenszentrum
Wissenszentrum
Back
Weiterbildung
Weiterbildung
Back
Sysmex Blogs
Sysmex Blogs
Back
Literatur
Literatur
Back
Menu
Headquarters
Sysmex Group Companies
Select your local website
Sysmex Suisse Akademie Sysmex Blogs Wissensblogs

Welcome to Sysmex Blogs

Life Science
ESR1 resistance mutations – What is the best technology for your patients?

ESR1 resistance mutations – What is the best technology for your patients?

Breast cancer is one of the most common types of cancer affecting women worldwide. In hormone receptor-positive, HER2-negative metastatic breast cancer, endocrine treatment has led to significant improvement in patient’s condition. However, tumors can develop resistance mechanisms throughout the therapy, for example via activating mutations in ESR1.

More information
Advancing precision oncology: sensitive detection of ESR1 mutations in plasma

Advancing precision oncology: sensitive detection of ESR1 mutations in plasma

Liquid biopsy offers a non-invasive method for detecting ESR1 mutations

More information
Liquid Biopsy impact: ctDNA applications in melanoma care

Liquid Biopsy impact: ctDNA applications in melanoma care

As we enjoy the summer and raise awareness about melanoma, this month's Impact discusses the latest scientific data on patient management. Hear directly from Dr. Isabel Heidrich and Dr. Christoffer Gebhardt about how liquid biopsy can be a valuable ally in the fight against melanoma.

More information
General
Sysmex Suisse AG
Tödistrasse 50
CH-8810 Horgen
+41 44 718 38 38
+41 44 718 38 39
info@sysmex.ch
Sysmex Suisse AG
Rue Galilée 15
CH-1400 Yverdon-les-Bains
+41 24 423 93 93
+41 24 423 93 98
info@sysmex.ch
Service
Social Media
Copyright © Sysmex Europe SE. All rights reserved.